Early acetaminophen administration is associated with lower mortality among ARDS patients after coronary artery bypass grafting: a retrospective study

Table 2 Correlation of early APAP use with 14-day, 30-day, 60-day, and 90-day mortality in CABG-ARDS cohort

Category	Models	HR	95%CI	P value
14-day mortality	Crude Model	0.184	0.108–0.313	< 0.001
	Model I	0.249	0.145–0.427	< 0.001
	Model II	0.281	0.162–0.485	< 0.001
	Model III	0.317	0.182–0.552	< 0.001
	Model IV	0.307	0.176–0.535	< 0.001
	Model V	0.329	0.187–0.577	< 0.001
30-day mortality	Crude Model	0.213	0.137–0.330	< 0.001
	Model I	0.293	0.188–0.458	< 0.001
	Model II	0.335	0.214–0.527	< 0.001
	Model III	0.373	0.236–0.587	< 0.001
	Model IV	0.363	0.230–0.573	< 0.001
	Model V	0.376	0.237–0.595	< 0.001
60-day mortality	Crude Model	0.291	0.204–0.415	< 0.001
	Model I	0.396	0.276–0.567	< 0.001
	Model II	0.441	0.307–0.634	< 0.001
	Model III	0.477	0.331–0.687	< 0.001
	Model IV	0.480	0.333–0.691	< 0.001
	Model V	0.497	0.343–0.718	< 0.001
90-day mortality	Crude Model	0.325	0.236–0.448	< 0.001
	Model I	0.437	0.315–0.605	< 0.001
	Model II	0.487	0.350–0.678	< 0.001
	Model III	0.526	0.377–0.732	< 0.001
	Model IV	0.535	0.384–0.746	< 0.001
	Model V	0.547	0.392–0.764	< 0.001

APAP, acetaminophen; CABG, coronary artery bypass grafting; ARDS, acute respiratory distress syndrome; HR, hazard ratio; CI, confidence interval
Adjusted covariates: Model I: ARDS, age, sex, race, admission type, surgery type, BMI. Model II: Model I + vital signs (heart rate, MAP, respiratory rate, temperature). Model III: Model II + laboratory tests (WBC, PLT, Hb, PH, PaO₂, PaCO₂). Model IV: Model III + comorbidities (congestive heart failure, diabetes, cerebrovascular disease, peripheral vascular disease, chronic pulmonary disease, chronic renal disease). Model V: Model IV + clinical scoring systems (OASIS, SIRS, SOFA)

ISSN: 1749-8090